(March 27, 2024, 11:03 AM EDT) -- ALEXANDRIA, Va. — A patent owner maintains in a March 26 petition for inter partes review (IPR) that it was the first to disclose, via inherency, a daily dose of ganaxolone for the treatment of status eliepticus (SE), or static seizure, and not a competitor....